ES2303287T3 - 4-((2,4-dicloro-5-metoxifenil)amino)-6-alcoxi-7-etinil-3-quinolinacarbonitrilos para el tratamiento de las lesiones isquemicas. - Google Patents

4-((2,4-dicloro-5-metoxifenil)amino)-6-alcoxi-7-etinil-3-quinolinacarbonitrilos para el tratamiento de las lesiones isquemicas. Download PDF

Info

Publication number
ES2303287T3
ES2303287T3 ES05820982T ES05820982T ES2303287T3 ES 2303287 T3 ES2303287 T3 ES 2303287T3 ES 05820982 T ES05820982 T ES 05820982T ES 05820982 T ES05820982 T ES 05820982T ES 2303287 T3 ES2303287 T3 ES 2303287T3
Authority
ES
Spain
Prior art keywords
amino
methoxyphenyl
dichloro
quinolinecarbonitrile
episode
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05820982T
Other languages
English (en)
Spanish (es)
Inventor
Diane Harris Boschelli
Margaret Zaleska
Ana Carolina Barrios-Sosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2303287T3 publication Critical patent/ES2303287T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
ES05820982T 2004-10-22 2005-10-21 4-((2,4-dicloro-5-metoxifenil)amino)-6-alcoxi-7-etinil-3-quinolinacarbonitrilos para el tratamiento de las lesiones isquemicas. Expired - Lifetime ES2303287T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62128004P 2004-10-22 2004-10-22
US621280P 2004-10-22

Publications (1)

Publication Number Publication Date
ES2303287T3 true ES2303287T3 (es) 2008-08-01

Family

ID=35784691

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05820982T Expired - Lifetime ES2303287T3 (es) 2004-10-22 2005-10-21 4-((2,4-dicloro-5-metoxifenil)amino)-6-alcoxi-7-etinil-3-quinolinacarbonitrilos para el tratamiento de las lesiones isquemicas.

Country Status (23)

Country Link
US (1) US20060116375A1 (enExample)
EP (1) EP1802581B1 (enExample)
JP (1) JP2008517924A (enExample)
KR (1) KR20070085413A (enExample)
CN (1) CN101044117A (enExample)
AT (1) ATE391122T1 (enExample)
AU (1) AU2005299822A1 (enExample)
BR (1) BRPI0516995A (enExample)
CA (1) CA2581807A1 (enExample)
CR (1) CR9072A (enExample)
DE (1) DE602005005843T2 (enExample)
DK (1) DK1802581T3 (enExample)
EC (1) ECSP077385A (enExample)
ES (1) ES2303287T3 (enExample)
IL (1) IL182547A0 (enExample)
MX (1) MX2007004833A (enExample)
NO (1) NO20071708L (enExample)
PL (1) PL1802581T3 (enExample)
PT (1) PT1802581E (enExample)
RU (1) RU2007111704A (enExample)
SI (1) SI1802581T1 (enExample)
WO (1) WO2006047262A1 (enExample)
ZA (1) ZA200703275B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
WO2014086284A1 (zh) * 2012-12-04 2014-06-12 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
CN114436851B (zh) * 2022-01-17 2023-08-22 常州大学 一种n,n-二甲基苄胺及其衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) * 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Also Published As

Publication number Publication date
SI1802581T1 (sl) 2008-08-31
BRPI0516995A (pt) 2008-09-30
NO20071708L (no) 2007-07-13
RU2007111704A (ru) 2008-11-27
KR20070085413A (ko) 2007-08-27
EP1802581B1 (en) 2008-04-02
PT1802581E (pt) 2008-06-03
DK1802581T3 (da) 2008-06-30
DE602005005843D1 (de) 2008-05-15
DE602005005843T2 (de) 2009-05-14
MX2007004833A (es) 2007-05-16
AU2005299822A1 (en) 2006-05-04
WO2006047262A1 (en) 2006-05-04
CR9072A (es) 2007-09-07
PL1802581T3 (pl) 2008-09-30
CA2581807A1 (en) 2006-05-04
ECSP077385A (es) 2007-05-30
CN101044117A (zh) 2007-09-26
IL182547A0 (en) 2007-09-20
US20060116375A1 (en) 2006-06-01
EP1802581A1 (en) 2007-07-04
JP2008517924A (ja) 2008-05-29
HK1104555A1 (en) 2008-01-18
ATE391122T1 (de) 2008-04-15
ZA200703275B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
ES2284964T3 (es) Nuevos derivados de indol-2-ona.
TWI659957B (zh) 新穎吡唑并［3,4-d］嘧啶化合物或其鹽
JP7669063B2 (ja) Ｂｔｋ阻害剤としての架橋二環式化合物
CN115557949A (zh) 四环类衍生物、其制备方法及其在医药上的应用
US20040229880A1 (en) 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
JP2020520925A (ja) 化合物、組成物および方法
KR100735781B1 (ko) 이소퀴놀린 화합물 및 그의 의약 용도
ES2303287T3 (es) 4-((2,4-dicloro-5-metoxifenil)amino)-6-alcoxi-7-etinil-3-quinolinacarbonitrilos para el tratamiento de las lesiones isquemicas.
JP2011511014A (ja) 新規な鎮痛剤としてのアリールメチリデン複素環
WO2023083269A1 (zh) 一种芳杂环类化合物及其应用
CN107652275B (zh) 喹唑啉衍生物及其制备方法和用途
HK1104555B (en) 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury
KR102218861B1 (ko) 단백질 키나아제 저해제인 신규한 페녹시 아로마틱 아마이드 유도체
EP0381508A2 (en) Use of cinnamamide for relaxing muscle tone
KR20030097833A (ko) Ｎ-(2,3-디메틸-5,6,7,8-테트라히드로푸로[2,3-ｂ]퀴놀린-4-일)-2-(2-옥소피롤리딘-1-일)아세트아미드의 다형체
JP2024510520A (ja) ダブルリング雑環ｆｇｆｒ４阻害剤、ダブルリング雑環ｆｇｆｒ４阻害剤を含有する医薬組成物と製剤、及びその用途
HK40042275A (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof
HK1257146B (en) Novel pyrazolo[3, 4-d] pyrimidine compound or salt thereof